Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Brainsway Ltd Reports Positive Final Results Of Study Using Deep TMS To Treat OCD


Wednesday, 4 Sep 2013 07:48am EDT 

Brainsway Ltd. announced that the final results of a clinical trial conducted at the Sheba Medical Center at Tel Hashomer to assess the efficacy of the Company's Deep TMS device in treating obsessive-compulsive disorder ("OCD") using a coil developed for this purpose. The double-blind, placebo-controlled study involved a total of 25 OCD patients that had previously failed to respond to both pharmacological and psychological therapy. The trial subjects were divided into three groups: a low-frequency treatment group, a high-frequency treatment group and a sham treatment group. The primary outcome measure for therapeutic efficacy was the change in patients' Yale-Brown Obsessive Compulsive Scale, or Y-BOCS, a standard test to rate the severity of OCD symptoms. In parallel, treated subjects underwent electroencephalography (EEG) measures in order to test objectively alterations in pathological neural activations that are associated with OCD. The clinical results showed an average improvement of 27% in symptoms of patients in the high-frequency treatment group, which was relative to the sham-control treated group (p=0.0003). 

Company Quote

3375.0
-70.0 -2.03%
1 Apr 2015